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Abstract
Background Psychostimulants remain first-line treatment
options for the management of attention-deficit/hyperac-
tivity disorder (ADHD). A multilayer extended-release
bead methylphenidate capsule (provisional name Aptensio
XRTM, MPH-MLR) with unique release properties is being
investigated for the treatment of ADHD.
Objective The aim of this study was to assess the efficacy
(primary) and safety and tolerability (secondary) of MPH-
MLR compared with placebo in children and adolescents
aged 6–18 years with ADHD.
Methods This study was a parallel, double-blind, multi-
center, placebo-controlled, forced-dose, phase III study in
which patients were randomized to placebo or MPH-MLR
10, 15, 20, or 40 mg given once daily. There were four
study phases: (1) 4-week screening/baseline; (2) 1-week,
double-blind treatment (DBP); (3) 11-week, open-label,
dose-optimization period; and (4) 30-day follow-up call.
During the open-label dose-optimization period all patients
started with MPH-MLR 10 mg, unless the investigator
deemed it necessary to begin at a higher dose, and were
titrated to an optimized dose (10, 15, 20, 30, 40, 50, 60 mg;
all given once daily) based on response and adverse events
(AEs). The primary endpoint was the change from baseline
to end of DBP in ADHD Rating Scale, 4th Edition
(ADHD-RS-IV) total score. Secondary endpoints included
changes in ADHD-RS-IV subscales and Clinical Global
Impression–Improvement Scale (CGI-I) at the end of the
DBP. The primary analysis was an analysis of covariance
including terms for treatment, site, and baseline ADHD-
RS-IV total score.
Results A total of 221 patients completed the DBP. The
primary endpoint had a statistically significant difference
among treatments (p = 0.0046) and sites (p = 0.0018),
and baseline covariate made a significant contribution
(p\ 0.0001). As the MPH-MLR dose increased, the
ADHD-RS-IV total score improved; the 20 and 40 mg
doses were statistically different (p = 0.0145 and
p = 0.0011, respectively) from placebo. Females re-
sponded differently than did males (p = 0.0238); there was
a significant difference among treatments for males but not
for females, partly because only one-third of subjects were
female and partly because some females who received
placebo had considerable improvement during the DBP.
Similarly, the ADHD-RS-IV subscales and CGI-I scores at
the end of the DBP also showed more improvement as the
dose of MPH-MLR increased. During the open-label phase,
ADHD-RS-IV total scores improved (mean change from
baseline -22.5) and correlated as the dose of MPH-MLR
increased; CGI-I scores also improved. No unexpected AEs
were noted.
Conclusions Dose-related improvements in ADHD-RS-
IV scores that exceeded those of placebo were observed in
patients treated with MPH-MLR. No new safety signals
were noted.
Trial Registration: ClinicalTrials.gov identifier NCT01239030.
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Key Points
Methylphenidate (MPH) multilayer bead extended-
release (ER) capsules (MPH-MLR; Aptensio XRTM)
administered once daily demonstrated significant
dose-related improvements in Attention-Deficit/
Hyperactivity Disorder Rating Scale, 4th Edition
(ADHD-RS-IV) scores compared with placebo in
children and adolescents with ADHD.
The safety profile of MPH-MLR is consistent with
other ER MPH formulations.
The results of this phase III study indicate that MPH-
MLR, with a novel release profile, offers a valuable
option for the treatment of ADHD in children and
adolescents.
1 Introduction
Nearly 6 million children and adolescents aged 3–17 years
in the USA have been diagnosed with attention-deficit/
hyperactivity disorder (ADHD) [1]. The practice guideline
from the American Academy of Pediatrics recommends
medication, including psychostimulants, for the manage-
ment of ADHD in this population [2]. Methylphenidate
(MPH) is a psychostimulant medication that is used ex-
tensively for the management of ADHD in children and
adolescents. Many formulations of MPH are available to
address the unique needs of this population.
Available extended-release (ER) formulations of MPH
provide different portions of the total dose as the imme-
diate-release (IR) component (20, 22, 30, and 50 %), as
well as different durations of action, allowing the pre-
scriber to tailor therapy to individual needs and responses
[3–5]. Inter- and intra-patient variabilities have been de-
scribed with these agents and contribute to the need for
MPH dose titration [6]. Response to treatment for ADHD is
individualized [7]; thus, new formulations of MPH con-
tinue to be investigated.
A novel ER formulation that incorporatesmultilayer beads
comprising 37 % of the labeled dose as IR MPH into ER
capsules (MPH-MLR;AptensioXRTM)1 has been developed.
Once-daily MPH-MLR is administered orally as intact cap-
sules or the capsule canbe opened and sprinkled on food, such
as applesauce. Pharmacokinetic studies have demonstrated
that following once-daily MPH-MLR administration, a
biphasic release profile ofMPH is observed [8, 9]. The initial
maximum (peak) concentration (Cmax) occurs approximately
2 h post-dose. A moderate decline in MPH concentration
occurs until approximately 5 h after dose administration and
then a second Cmax occurs at about hour 7. Overall, MPH-
MLR produced a better fluctuation index (less variability)
than IR MPH (Ritalin, Novartis Pharmaceuticals Corpora-
tion, East Hanover, NJ, USA) administered three times daily
[8, 9]. Intra-subject coefficients of variation were slightly
higher (44–136 %) for MPH-MLR during the first 2 h post-
dose in the absorption phase compared with the IR product
(20–112 %) on day 1 of a 4-day steady-state pharmacokinetic
study, but were quite similar after reaching Cmax and
demonstrably tighter through day 4 for MPH-MLR
(28–56 %) compared with the IR reference comparator
(26–108 %) [8, 9]. Clinical benefit of MPH-MLR, measured
in children aged 6–12 years in a laboratory classroom setting,
was evident from at least hour 1 (first assessment point)
through to the hour 12 final study assessment point [10].
To better understand the potential application of MPH-
MLR in the outpatient setting, the pharmacokinetic profile
of MPH-MLR must be linked with clinical outcomes. The
objective of this study was to assess the efficacy of MPH-
MLR compared with placebo in the clinic setting as mea-
sured by the clinician-administered ADHD Rating Scale,
4th Edition (ADHD-RS-IV) in children and adolescents
aged 6–18 years with ADHD. Evaluation of the safety and
tolerability of MPH-MLR during the 1-week double-blind
study period was a secondary objective.
2 Methods
2.1 Study Conduct
This study was conducted at 16 sites in the USA from
December 2010 to November 2011 (ClinicalTrials.gov
identifier NCT01239030 [11]). The study protocol,
amendments, and informed consent form were reviewed
and approved by an Institutional Review Board for each
study site. The study was conducted in compliance with
Good Clinical Practice (GCP) guidelines of the Interna-
tional Conference on Harmonization of Technical Re-
quirements for Registration of Pharmaceuticals for Human
Use, the United States Code of Federal Regulations that
relate to clinical trial conduct, and the principles of the
Declaration of Helsinki. All patients and/or their guardians
provided informed consent prior to screening assessments.
2.2 Study Patients
Children and adolescents (male and female) aged
6–18 years at time of consent with an ADHD diagnosis
1 Rhodes Pharmaceuticals L.P. has received conditional acceptance
from the US FDA to use the name Aptensio XRTM for this ER MPH
product.
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of all subtypes (except Not Otherwise Specified) as de-
fined in the Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition, Text Revision (DSM-IV-TRTM)
[12] were included if they met defined inclusion and
exclusion criteria. ADHD diagnosis was supported by the
Schedule for Affective Disorders and Schizophrenia for
School-Age Children—Present and Lifetime version (K-
SADS-PL) [13]. Recorded baseline ADHD-RS-IV total or
subscale scores had to be C90th percentile relative to the
general population of children by age and sex at
screening or baseline. Patients had to require pharmaco-
logical treatment for ADHD.
Exclusion criteria included an Estimated Full Scale
intellectual level\80 using the four-subtest form of the
Wechsler Abbreviated Scale of IntelligenceTM
(WASITM) [14], and a current primary psychiatric di-
agnosis of severe anxiety disorder, conduct disorder,
psychotic disorder, pervasive developmental disorder,
eating disorder, obsessive-compulsive disorder, major
depressive disorder, bipolar disorder, substance use
disorder, chronic tic disorder, or a personal or family
history of Tourette’s syndrome as defined by the DSM-
IV-TR criteria and supported by the K-SADS-PL. Pa-
tients with a chronic medical illness (seizure, cardiac
disorders, untreated thyroid disease, glaucoma), using
monoamine oxidase inhibitors or psychotropic medica-
tion within 14 days of screening or another ex-
perimental drug or device within 30 days of screening,
who had a clinically significant electrocardiogram
(ECG) or clinical laboratory abnormality at screening
and/or baseline, or who were pregnant or lactating were
also excluded from the study.
2.3 Study Treatments
All study treatments (MPH-MLR 10, 15, 20, 30, 40, 50,
60 mg, placebo) were given orally once daily in the
morning, no later than 10 a.m. and were packaged in bot-
tles of ten capsules for a 1-week dispensing interval and
bottles of 30 for 4- and 8-week dispensing intervals. Lot
numbers used during the double-blind phase were A07983-
002L01 (10 mg), A07983-002L02 (15 mg), A07983-
002L03 (20 mg), A07983-002L04 (40 mg), and A07983-
001L02 (placebo). During the open-label phase the fol-
lowing lot numbers were used: 10 mg, A07983-003L01
(10 Ct), A07983-005L01 (30 Ct); 15 mg, A07983-003L03
(10 Ct), A07983-003L03 (30 Ct); 20 mg, A07983-003L06
(10 Ct), A07983-005L05 (30 Ct); 30 mg, A07983-003L08
(10 Ct), A07983-005L07 (30 Ct); 40 mg, A07983-003L10
(10 Ct), A07983-005L09 (30 Ct); 50 mg, A07983-006L01
(30 Ct); and 60 mg, A07983-006L0 (30 Ct).
2.4 Study Design
The study included four distinct phases: screening, double-
blind, open-label, and safety follow-up.
The screening phase (up to day -28, visit 1) comprised
the initial study visit. During this visit, informed consent
and medical and psychiatric histories were obtained, vital
signs, baseline physical examination and ECG were per-
formed, and serum chemistry and hematology measure-
ments were collected. The K-SADS-PL, WASITM, and the
baseline Columbia Suicide Severity Rating Scale (C-SSRS)
[15] were assessed. For patients receiving ADHD
medications at study entry, a washout period of 48 h
(minimum) was initiated prior to beginning the double-
blind phase.
The double-blind, forced-dose phase began on day 0
(visit 2), which included baseline assessments (Table 1),
recording of body weight and vital signs, and 12-lead ECG.
Patients received their randomized, fixed dose of MPH-
MLR or placebo for the 1-week, double-blind phase.
Dosing began at home in the morning on day 1. During this
phase, patients were randomized (1:1:1:1:1) to receive
MPH-MLR 10, 15, 20, or 40 mg or placebo following a
computer-generated randomization schedule with patients
assigned the next random number arranged in an ABCDE
block design with each letter representing one of the five
treatment groups. There was no site stratification in ran-
domization. Patients weighing B25 kg were not assigned to
receive the 40 mg dose. This phase concluded on day 7 or
later (?3 days, visit 3). At this time, post-double-blind
assessments were done (Table 1) and patients who com-
pleted the double-blind phase had the option of continuing
on to the open-label phase.
Patients choosing to continue to the open-label (dose-
optimization) phase had treatment initiated with a once-
daily MPH-MLR 10 mg dose unless the investigator
deemed it necessary to begin at a higher dose based on
previous treatment experience. Patients returned to the
clinic at weekly intervals (range 3–7 days) through the first
3 weeks (weeks 2, 3, 4; visits 4, 5, and 6) of the open-label
period. Additional mandatory visits occurred at week 8
(visit 7) and the end of week 12 (visit 8, end of open-label
period). Unscheduled visits were permitted for additional
dose titration as needed. The investigator titrated (up or
down) the dose of MPH-MLR based on ADHD-RS-IV and
Clinical Global Impression (CGI)–Improvement Scale
(CGI-I) scores, tolerability, and clinical judgment until the
optimal dose was achieved. MPH-MLR capsules of 10, 15,
20, 30, 40, 50, and 60 mg were available in the open-label
phase. The Since-Last version of the C-SSRS was used at
all visits during this phase.
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A follow-up telephone call was made 30 days (±7 days)
following the patient’s last dose of study medication.
During the call, patients and/or their guardians were asked
about new or unresolved adverse events (AEs) since the
last study visit and new medications started since the last
study visit.
AEs were collected at each visit. Safety assessments
included vital signs, physical examination, ECG, clinical
laboratory evaluations, C-SSRS, and AEs.
2.5 Assessments
To interview the parent or guardian, clinicians at each site
were instructed to use the ADHD-RS-IV, an 18-item scale
that rates symptoms of ADHD as outlined in the DSM-IV-
TR [16]. Each symptom is rated on a scale of 0–3:
0 = never or rarely; 1 = sometimes; 2 = often; and
3 = very often. A total score is calculated from a sum of
individual scores with total score ranging from 0 (no im-
pairment) to 54 (maximal impairment). Scoring can also be
broken into subcategories of inattention and hyperactivity-
impulsivity. During the double-blind and open-label
phases, clinician raters were instructed to do their best to
perform ratings on the same children and adolescents.
The CGI is a clinician-administered tool used to assess
the symptoms of ADHD [17]. The tool provides a scoring
of initial severity on the CGI–Severity Scale (CGI-S) from
1 to 7; subsequent improvements over time during treat-
ment are rated using the CGI-I. Scoring for the CGI-S is as
follows: 1 = normal, not ill at all; 2 = borderline ill;
3 = mildly ill; 4 = moderately ill; 5 = markedly ill;
6 = severely ill; and 7 = among the most extremely ill
patients. At subsequent study visits, clinicians used the
CGI-I 7-point scale to rate the patients’ total improvement
based on comparison with their baseline assessment from
1 = very much improved to 7 = very much worse. In this
study, each clinical rater established target symptoms on
which to anchor the CGI using baseline clinical problems
specific to each individual child enrolled in the study.
2.6 Endpoints
The primary efficacy endpoint measure was change from
baseline to end of the double-blind period in the clinician-
rated ADHD-RS-IV total score. Secondary endpoints in-
cluded change from baseline to end of the double-blind
period in ADHD-RS-IV subscales of Inattention and
Hyperactivity and CGI-I at the end of the double-blind
period. Exploratory endpoints included the ADHD-RS-IV
total score and subscale scores during weeks 3 through 12
(during the open-label period), assessment of CGI-I at the
same timepoints, and an evaluation of the final open-label
MPH-MLR dose vs. body weight.
2.7 Statistical Analysis
The safety/intent-to-treat (ITT) population included all
patients who took at least one dose of study medication.
The efficacy population included all patients who com-
pleted the double-blind phase.
The primary efficacy analysis was an analysis of co-
variance (ANCOVA) of the decrease in ADHD-RS-IV
total score during the double-blind phase using the efficacy
population. The model had class terms for treatment (five
levels), site (sites with less than ten patients were combined
into a pseudo site), and a covariate term for baseline
ADHD-RS-IV total score. The same model was applied to
the ITT population as a sensitivity analysis. Subjects not
completing the double-blind phase had the decrease in total
score set to zero for the sensitivity analysis.
The key secondary efficacy analysis was a follow-up to
the primary analysis using the efficacy population, and
each MPH-MLR dose level was compared to placebo using
Dunnett’s multiple comparison to control procedure with
the family-wise type I error (two-sided) rate set at 0.05. A
sensitivity analysis was conducted using the ITT popula-
tion. Secondary analyses analyzed the ADHD-RS-IV sub-
scales and CGI-I during the double-blind phase using the
efficacy population. The ANCOVA model had terms for
Table 1 Clinical assessments Phase I: screening Phase II: double-blind Phase III: open-label




CGI-I X X X X X X
ADHD-RS-IV (clinician rated) X X X X X X X X
C-SSRS X X X X X X X
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, CGI-I Clinical Global
Impression–Improvement Scale, CGI-S Clinical Global Impression–Severity Scale, C-SSRS Columbia-
Suicide Severity Rating Scale, K-SADS-PL Schedule for Affective Disorders and Schizophrenia for School-
Age Children—Present and Lifetime Version, WASITM Wechsler Abbreviated Scale of IntelligenceTM
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treatment and site, and the covariate was either the baseline
score for the ADHD-RS-IV subscale or the baseline CGI-S
score. Comparison of treatments at baseline was accom-
plished using an analysis of variance (ANOVA) with terms
for treatment and site.
The ANCOVA for the subgroup analysis of ADHD-RS-
IV included the main effects of treatment, site, age, sex,
race, and the interactions of site by treatment, age by
treatment, sex by treatment, and race by treatment, as well
as the covariate baseline score.
Open-label phase data were summarized descriptively.
A linear regression of the final open-label dose on body
weight was performed.
It was estimated that a total sample size of 225 would
have 80 % power to detect a mean difference in ADHD-
RS-IV score between treatment and placebo of 8, based on
a standard deviation (SD) of 14.
3 Results
3.1 Patients
Of the 280 children who were screened, 230 entered the
double-blind phase and were administered one of the four
strengths of MPH-MLR or placebo (10 mg, n = 49;
15 mg, n = 44; 20 mg, n = 45; 40 mg, n = 45; placebo,
n = 47). Most patients were male (67 %) and were pre-
dominantly white (69 %) (Table 2). The average age was
10.8 years: 60 children were 6–8 years, 76 were
9–11 years, 63 were 12–14 years, and 31 were
15–18 years. The most common ADHD diagnosis subtype
was combined (61 %), with 33 % diagnosed as pre-
dominantly inattentive. The most common psychiatric co-
morbidities were oppositional defiant disorder (n = 22)
and enuresis (n = 14). 221 children completed the 1-week
double-blind phase and were included in the efficacy
population (Fig. 1) and 200 completed the open-label
phase.
3.2 Efficacy
At baseline (visit 2), there was no significant difference
among treatments for either ADHD-RS-IV total score
(ANOVA, p = 0.1284) or CGI-S scores (ANOVA,
p = 0.1122) (Table 3). There was a significant difference
among sites for ADHD-RS-IV total score (ANOVA,
p = 0.0197) and CGI-S (ANOVA, p\ 0.0001). CGI-S
scores revealed a population with substantial disease as
[90 % of patients scored as moderately or markedly ill.
The primary efficacy analysis showed that the mean
decrease in ADHD-RS-IV total score from baseline to the
end of the double-blind phase differed among treatments
(Fig. 2a). There were statistically significant differences
(ANCOVA) among treatments (p = 0.0046), significant
differences among sites (p = 0.0018), and the baseline
covariate made a significant contribution to the model
(p\ 0.0001). The sensitivity analysis produced similar
results, reporting a statistically significant difference
among treatments (p = 0.0078).
Key secondary endpoint analysis demonstrated de-
creases in ADHD-RS-IV total score that were significantly
different from placebo for the 20 mg (p = 0.0145) and
40 mg (p = 0.0011) MPH-MLR doses, while the 10 mg
(p = 0.2083) and 15 mg (p = 0.0769) doses were not
significantly different from placebo.
The mean decrease during the double-blind phase for
hyperactivity/impulsivity and inattention subscale scores
Table 2 Patient demographic characteristics (safety population, n = 230)














10.5 (2.9) 10.2 (3.1) 11.1 (3.5) 11.2 (2.5) 10.9 (3.0) 10.8 (3.0)
Males [n (%)] 30 (61.2) 30 (68.2) 31 (68.9) 33 (73.3) 30 (63.8) 154 (67.0)
Race [n (%)]
White 34 (69.4) 26 (59.1) 33 (73.3) 32 (71.1) 33 (70.2) 158 (68.7)
Black 13 (26.5) 11 (25.0) 9 (20.0) 11 (24.4) 9 (19.1) 53 (23.0)
Asian 0 2 (4.5) 0 0 1 (2.1) 3 (1.3)
Other 2 (4.1) 5 (11.4) 3 (6.7) 2 (4.4) 4 (8.5) 16 (7.0)
Body weight (kg)
Mean (SD) 43.8 (19.5) 44.6 (21.7) 45.7 (20.6) 48.8 (18.7) 40.5 (14.4) 44.6
(19.1)
Min., max. 20.5, 102.5 16.8, 125.5 18.5, 95.5 27.0, 114.5 21.6, 81.8 16.8,
125.5
max. maximum, min. minimum, MPH-MLR methylphenidate multilayer extended-release capsules, SD standard deviation
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demonstrated between-treatment differences that were
similar to the primary endpoint (Fig. 2b, c, respectively).
ANCOVA testing found statistically significant differences
among treatments for hyperactivity/impulsivity
(p = 0.0240) and inattention (p = 0.0080). The follow-up
pairwise comparison of treatments showed that the MPH-
MLR 40 mg dose was significantly different from placebo
for both subscales (p = 0.0061 hyperactivity/impulsivity,
p = 0.0026 inattention), and the MPH-MLR 20 mg dose
was significantly different from placebo for the inattention
subscale (p = 0.0118).
Subset analyses that examined the decrease in ADHD-
RS-IV total score over the double-blind period revealed no
difference among treatment groups for all sites, all age
groups, and all races. Females responded differently than
males (p = 0.0238); there was a significant difference
among treatments for males but not for females, partly
because only one-third of subjects were females and partly
because some females who received placebo had consid-
erable improvement during the double-blind phase. Three
of 17 female patients in the placebo group had markedly
high values for the ADHD-RS-IV total score at baseline
and very low scores for the ADHD-RS-IV total score at the
end of the double-blind period.
CGI-I scores at the end of the double-blind phase also
showed more improvement as the dose of MPH-MLR in-
creased (Fig. 3). From the ANCOVA, there was a sig-
nificant difference among treatments (p = 0.0121) and
among sites (p = 0.0004), but the covariate baseline CGI-S
did not have a significant contribution (p = 0.1029).
Pairwise difference from placebo was significant for both
the 20 mg (p = 0.0311) and 40 mg (p = 0.0072) doses but
not for the 10 mg (p = 0.7391) or the 15 mg (p = 0.5518)
doses.
Throughout the open-label period, ADHD-RS-IV total
scores decreased (Fig. 4). At the end of the open-label
period, mean (SD) ADHD-RS-IV total scores were 13.5
(8.65), a decrease of 22.5 from baseline.
CGI-I scores improved during the open-label period
(Fig. 5). The ADHD-RS-IV total score and the mean MPH-
MLR dose during the open-label period are plotted in
Fig. 6. The mean ADHD-RS-IV total score decreased and
the MPH-MLR doses increased as the open-label phase
proceeded.
3.3 Final Open-Label Dose
The most common final open-label dose was 30 mg
(27.7 %) followed by 40 mg (25.2 %), 50 mg (17.8 %),
20 mg (16.8 %), 60 mg (8.9 %), 15 mg (2.0 %), and
10 mg (1.5 %). No relationship between the final open-
label phase dose and body weight was observed (linear
regression, slope p = 0.1039).
3.4 Safety
The most common AEs during the double-blind phase in-
cluded headache, insomnia, and upper abdominal pain
(Table 4). Most events were mild or moderate in severity.
Three severe AEs were reported: insomnia by two patients
receiving MPH-MLR 40 mg and crying in one patient re-











Screening not completed, n = 26
Failed screening, n = 14
Passed screening, no drug dispensed, n = 10
Adverse events, n = 3
Lost to follow-up, n = 2
Withdrew consent, n = 3
Withdrawn owing to noncompliance, n = 1
Adverse events, n = 9
Lost to follow-up, n = 3
Withdrew consent, n = 8
Withdrawn owing to noncompliance, n = 1
Fig. 1 Patient disposition













CGI-S 4.48 (0.65) 4.70 (0.65) 4.59 (0.62) 4.47 (0.63) 4.35 (0.64)
ADHD-RS-IV
Inattention 21.2 (4.09) 21.1 (4.15) 21.1 (4.45) 20.1 (4.78) 18.8 (5.30)
Hyperactivity/
impulsivity
16.5 (6.14) 16.8 (6.55) 15.1 (7.30) 15.5 (6.43) 14.6 (7.75)
Total 37.6 (8.32) 38.0 (8.64) 36.2 (8.46) 35.6 (9.16) 33.4 (11.01)
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, CGI-S Clinical Global Impression–Severity Scale, MPH-MLR
methylphenidate multilayer extended-release capsules, SD standard deviation
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AEs during the open-label phase were decreased appetite
(19.0 %), headache (17.6 %), insomnia (11.8 %), upper
abdominal pain (10.9 %), upper respiratory tract infection
(6.3 %), irritability (5.4 %), and fatigue (5.0 %); most
were mild or moderate in severity. Four patients experi-
enced a severe AE during the open-label phase: viral gas-
troenteritis (n = 1) and viral infection (n = 1), both of
which were unrelated to study treatment, and aggression
(n = 1) and mood swings (n = 1), which were related to
study treatment.
One serious AE was reported during the double-blind
phase. One patient receiving MPH-MLR 15 mg was hos-
pitalized for adjustment disorder with mixed disturbance of
emotion and conduct not considered to be related to the
study drug. Additionally, one serious AE was reported
during the open-label phase. A patient receiving MPH-
MLR 30 mg was diagnosed with an injury-related migraine
headache not considered to be related to study drug. Both
patients with serious AEs withdrew from the study at the
time of the event. Additional safety assessments did not
reveal any unexpected results beyond the known AE profile
for this class of medication.
4 Discussion
Results of this randomized, parallel, double-blind, placebo-
controlled study demonstrated that MPH-MLR produced
symptom improvement evidenced by ADHD-RS-IV total
scores when given to children and adolescents aged
6–18 years with ADHD. Improvements in ADHD-RS-IV
total scores correlated with increasing doses of MPH-MLR.
Similarly, CGI-I scores indicated bigger improvements as
the MPH-MLR dose increased. The two highest MPH-
MLR doses yielded significant improvement on the
ADHD-RS-IV total score and CGI-I compared with
placebo. Although the two lower MPH-MLR doses did not
show improvement that was significantly different from
placebo, the five treatments descriptively indicated more
improvement with higher MPH-MLR doses. The study was
not powered to demonstrate a significant difference from
placebo for every MPH-MLR treatment group. The finding
that the two lowest-dose groups were not significantly
different from placebo during the double-blind phase may
reflect that only 3.5 % of patients had dose levels of 10 or
15 mg at the end of the open-label (dose-optimization)
phase.
MPH-MLR composition (37 % immediate release) in a
10 or 15 mg tablet would result in 3.7 or 5.55 mg of MPH
being immediately available, respectively. Treatment im-
provement in all patients with ADHD would not be ex-
pected at these doses. Rather, lower doses are important for
dose optimization in the naturalistic clinic setting to permit
slow titration to efficacy; this is particularly important for
treatment-naı¨ve and younger patients. The randomization
forced-dose schedule used in this study did not account for







































































































































Fig. 2 Mean decrease in ADHD-RS-IV total score (a); hyperactivity
subscale score (b); and inattention subscale score (c) from baseline
(day 0) to the end of the double-blind phase (day 7; efficacy
population; n = 221). ADHD-RS-IV Attention-Deficit/Hyperactivity
Disorder Rating Scale, 4th Edition, MPH-MLR methylphenidate
multilayer extended-release capsules. *p = 0.0145 vs. placebo;
**p = 0.0011 vs. placebo; p = 0.0840 vs. placebo; p = 0.0061
vs. placebo; p = 0.0118 vs. placebo; p = 0.0026 vs. placebo
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It is difficult to directly compare ER formulations of
MPH across independent clinical research studies as study
designs and outcome measures vary. However, evaluations
of other ER MPH formulations using the ADHD-RS-IV
have reported improvements similar to those observed in
this study [18, 19]. In our study of MPH-MLR, when each
patient’s dose was optimized, the mean ADHD-RS-IV total
score was 13.5 for a decrease of 22.5 from baseline.
Similarly, at the end of the open-label period of a ran-
domized controlled study using MPH ER oral suspension
(MEROS) in children and adolescents aged 6–12 years,
those patients receiving MEROS had improved from a
mean (SD) of 39.3 (7.6) at baseline to 12.6 (6.3) [19]. In a
phase III study of MPH transdermal system (MTS),
ADHD-RS-IV was assessed in children aged 6–12 years
with ADHD [18]. Significant improvements in ADHD-RS-
IV total scores were reported for children randomized to
MTS as well as to the active comparator [osmotic-release
oral system (OROS)] compared with placebo over the
7-week study period. ADHD-RS-IV scores improved from
43.0, 43.9, and 41.9 to 18.18, 12.8, and 32.1 for MTS,
OROS, and placebo, respectively.
We found improvements in ADHD-RS-IV and CGI-I
appeared to be dose-related, although the 10 and 15 mg
doses did not achieve statistical significance during the
1-week double-blind phase. Further statistical analysis did
not identify a relationship between the optimal dose at the
end of the open-label period and body weight. However, a
separate analysis using a population pharmacokinetic
model including data from this study showed a correlation
between body weight [ranging from 20 to 80 pounds
(9–36 kg)] and change from baseline in ADHD-RS-IV
score [20]. Although additional studies are needed to in-
vestigate this relationship, this information may be useful
to clinicians who are initiating therapy with MPH-MLR.
One treatment goal of pharmacotherapy for ADHD is to
provide children and adolescents with the ability to func-
tion more effectively. Since school is one of the key set-
tings for this age group, functionality in children and
adolescents with ADHD has often been evaluated in the
laboratory school setting [21]. MPH-MLR was evaluated in
this setting in a randomized, double-blind, controlled,
crossover study that included 20 children aged 6–12 years

































3 Very much improved = 1 Much improved = 2 Minimally improved = 3 No change = 4Fig. 3 Mean CGI-I scores at
end of the double-blind phase
(day 7: efficacy population;




capsules, SD standard deviation.
*p = 0.0311 vs. placebo;
























Fig. 4 Arithmetic mean ADHD-RS-IV total scores (lower numbers
indicate improvement) from 1 week following the beginning of open-
label dose optimization (visit 4) to the end of the open-label phase
(visit 8) (efficacy population; n = 221). ADHD-RS-IV Attention-
Deficit/Hyperactivity Disorder Rating Scale, 4th Edition









































Fig. 5 Arithmetic mean CGI-I scores from 1 week following the
beginning of open-label dose optimization (visit 4) to the end of the
open-label phase (visit 8) (efficacy population; n = 221). CGI-I
Clinical Global Impression-Improvement Scale
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significant decrease in Swanson, Kotkin, Agler, M-Flynn,
and Pelham (SKAMP) scores (p = 0.0001) compared with
placebo, suggesting that symptoms of ADHD in the studied
children improved with treatment. The current study con-
ducted in a less-structured clinic setting adds to these
previously published data.
When administered once daily, MPH-MLR was safe and
well-tolerated during the fixed-dose, double-blind phase.
Overall, there were no new or unexpected safety signals
identified in the study and reported AEs are consistent with
the known AE profile of MPH. While there are many
psychostimulants available on the market, the unique re-
lease pattern of MPH-MLR offers clinicians another option
for their patients with ADHD.
Strengths of this study included the large number of
patients from multiple sites and use of validated efficacy
measures to evaluate response to treatment. However,
study participation criteria, particularly the exclusion of
patients with a co-morbid psychiatric condition requiring
medication treatment, although similar to other ADHD
clinical trials, limit the generalizability of the findings to
the general population of children and adolescents with
ADHD. Also, fixed dosing used during the double-blind
phase might have resulted in study patients who were over-
or under-treated with MPH-MLR. The double-blind period
was short and, overall, the study duration was only
12 weeks, thus limiting a clear understanding of long-term
efficacy. The brief washout period (2 days), while equaling
or exceeding at least five half-lives for ADHD medications
patients may have been using prior to study entry, may
have resulted in inflated baseline scores for some patients
as it is possible that there were residual pharmacodynamic
changes at receptor sites.
5 Conclusions
In this study, the use of MPH-MLR in children and adoles-
cents aged 6–18 years with ADHD led to improvements in
ADHD-RS-IV scores that were larger than those observed in
placebo-treated patients during a 1-week double-blind
evaluation in a dose-related pattern. Improvements contin-
ued over a subsequent 11-week open-label study period. No
new safety signals were observed. Results indicate that
MPH-MLR is a viable treatment option,with a release profile
that differs from currently marketed psychostimulants, sig-
nificantly improving symptoms of ADHD, with an AE pro-
file comparable to other MPH products.
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g)Fig. 6 Mean ADHD-RS-IV
total score and mean MPH-
MLR dose from 1 week
following the beginning of
open-label dose optimization
(visit 4) to the end of the open-
label phase (visit 8) (patients
completing open-label phase,
n = 200). ADHD-RS-IV
Attention-Deficit/Hyperactivity

















Abdominal pain upper 4 (8.2) 4 (9.1) 6 (13.3) 1 (2.2) 0 (0)
Nausea 3 (6.1) 0 (0) 2 (4.4) 2 (4.4) 1 (2.1)
Vomiting 3 (6.1) 2 (4.5) 1 (2.2) 1 (2.2) 0 (0)
Decreased appetite 1 (2.0) 2 (4.5) 4 (8.9) 2 (4.4) 0 (0)
Dizziness 0 (0) 4 (9.1) 0 (0) 0 (0) 1 (2.1)
Headache 6 (12.2) 3 (6.8) 6 (13.3) 5 (11.1) 4 (8.5)
Insomnia 5 (10.2) 2 (4.5) 6 (13.3) 5 (11.1) 1 (2.1)
MedDRA The Medical Dictionary for Regulatory Activities, MPH-MLR methylphenidate multilayer extended-release capsules
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